Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine for Chronic Hepatitis B
NCT00001457Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Sep 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lamivudine in Chronic Hepatitis B (CHB) and chronic hepatitis D, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Hepatitis B Virus DNA Levels at 5 years, Hepatitis D Virus RNA Levels at 5 years and 2 more. Started Sep 1995; status: completed.
02
Drugs
lamivudine
03
Conditions
Chronic Hepatitis B (CHB)chronic hepatitis D
Beyond the preview
Go deeper on NCT00001457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001457.